INTRODUCTION
Pharmaceutical biotechnology which is an interdisciplinary, specific and innovative field of pharmaceutics is developing rapidly both in academic institutions and in the pharmaceutical industry. In the Pharmacy field, biotechnology has been used to develop novel diagnostics and therapeutics for healthcare. The increasing importance of this technology in healthcare is affecting almost every aspect of pharmacy practice. Pharmaceutical biotechnology has conce-*Address correspondence to this author at the Hacettepe University -ntrated primarily on recombinant DNA technology, monoclonal antibodies, vaccines and gene therapy. Hundreds of employees now work at more than 1000 biotechnology companies in the USA and academic scientists, personnel of the government laboratories and biotechnology centers are not included in this number. Academic research has focused on biotechnology derived drug products and companies, which dealt with traditional drugs in the past, have now become more involved in biopharmaceuticals. New working associations have also been established between industry and universities. Basic and applied research in pharmaceutical biotechnology generates knowledge that is applied to the needs of the society. A number of pharmaceutical biotechnology books have been written. Moreover, graduate / undergraduate courses and programs have been initiated in some Pharmacy Faculties around the world [1] [2] [3] [4] [5] .
Taking into consideration this rapid development, FIP Special Interest Group of Pharmaceutical Biotechnology decided to develop a questionnaire concerning pharmaceutical biotechnology education in order to determine its present status and future needs [6] . The objectives of this worldwide questionnaire study v'ere to review all of the undergraduate courses and textbook references / scientific sources which are presently available in the area of pharmaceutical biotechnology. One of the major aim was to determine the borders and milestones of pharmaceutical biotechnology in pharmacy education from both a qualitative and quantitative aspect.
The prepared questionnaires were distributed to leading" scientists in academia and research directors or senior managers of Pharmaceutical Biotechnology companies to gather their opinions about how to create a satisfactory educational program in this field. The proposed undergraduate teaching program in pharmaceutical biotechnology mainly involved nine topics. The questionnaire consisted of 10 questions regarding the teaching of pharmaceutical biotechnology in undergraduate programs in academic institutions (Appendix I). The questionnaires were sent to 110 faculties/firms in 18 countries in Asia, Euiv;pe and America and a total 52 replies were received (Table la and Ib) .
The data was evaluated and the outcome of the questionnaires showed that educational efforts in training qualified staff in the rapidly growing field of pharmaceutical biotechnology is quite promising.
METHODS
After completing the preliminary studies for the formatting of the questionnaires, drafts were sent for review and feed-back to leading scientists who were pioneers of this area to seek their views. After revision and he questionnaires were In 1996 another collaborative survey with the European Association of Faculties of Pharmacy (EAFP) was completed successfully by our department on "Developing Teaching Objectives in Pharmaceutical Technology". Since pharmaceutical technology is a well-established program that is included in the curriculum of almost all pharmacy schools around the world but since this was an EAFP survey, the questionnaire only covered the Pharmacy schools in Europe. However, when preparing this present survey on pharmaceutical biotechnology we had to undertake a global survey as this is a new program which is in the establishment phase in most academic institutions.
We distributed this questionnaire on "Current Status and Future Needs of Pharmaceutical Biotechnology Education" to 110 institutions (academic & companies). Distribution of the questionnaires was in two parts. In the first phase a total of 56 questionnaires were distributed while 21 replies were received. In the second part of the survey, a total of 54 questionnaires were distributed and 31 replies were returned. In total 110 questionnaires were distributed and 52 responses were evaluated. Tables la and Ib show the distribution of the survey. Questionnaires were sent to 13 countries in Europe, 2 countries in America and 3 countries in Asia. 27 replies were received from Europe; 5 being from industry, 22 from academic institutions. From America, 11 from academic institutions, 7 from industry. Finally from Asia 7 replies were received, all from academic institutions. We evaluated 52 replies and estimated the reasons for failing to set all to replies to be:
It is practically current impossible to get 100 % response for such a survey. -In most of the pharmacy schools to which the questionnaire was sent, there were no pharmaceutical biotechnology courses in their pharmacycurriculum. (Table lb) . Contd ….. It was our approach to send the questionnaires to some of the academic institutions even though we already knew that they did not have biotechnology courses in their pharmacy curriculum to obtain their opinion about this new and rapidly developing field of pharmaceutical sciences and to leam whether they had plans for designing such a program.
Yes (hrs / week)
Pharmaceutical biotechnology related companies were targetted because we had a strong belief that (see the related question in the questionnaire) industry-academia collaboration is required in this area. After completing the survey, incoming data was evaluated and tabulated for presentation and discussion.
RESULTS & DISCUSSION
Regarding the question about including pharmaceutical biotechnology courses in Pharmacy teaching programs of Pharmacy faculties, all of the respondents from faculties and companies (America, Asia and Europe) were in agreement about the inclusion of pharmaceutical biotechnology courses in undergraduate teaching programs of pharmacy faculties. Here it is important to note that all of the academic institutions and related companies were well aware of the significance and status of this novel and advancing field in pharmacy teaching programs.
In a previous survey, EUFEPS Committee on Industrial Relations (CIR) was asked by the Executive Committee to search for the problems faced when recruiting qualified personnel at the post doctorate levels in the pharmaceutical industry [7] . As a result of this survey it was concluded that there was a great shortage of qualified candidates at Ph.D. level in the pharmaceutical biotechnology area. In fact, Ph.D. programs of pharmaceutical biotechnology in pharmacy schools are in their infancy and in the near future qualified Ph.D. personnel will be needed to fullfil the demand. Replies from Asia appeared to be more variable since some of the respondents' suggestions indicated that courses should be optional in undergraduate programs. Most of the respondents suggested a 2-4 hrs / week for the duration of courses while the generally suggested initiation time was the 3 rd year of the pharmacy undergraduate program.
APPENDIX
Evaluation of the responses from Europe showed that suggestions for the duration of courses was variable from 1-7 hrs/week, while the initiation time of courses was proposed to be the 3 rd and 4 th years. However, almost 50 % of the respondents suggested that these should be optional. Differences in the approaches of the universities and related companies in America, Asia, Europe might be due to the variance in the duration of the pharmacy education in these countries. For thorough examination of the replies regarding the year-semester distributions of ( The percentage of pharmaceutical biotechnology courses in the total pharmacy education program was another important consideration of this survey. The percentage distribution of the replies showed a wide range of opinions: 5-10 % in Europe 10-20 % in Asia and 5-10 %. in USA This may be related to the approach and involvement of the respondent country at the industrial and academic level in pharmaceutical biotechnology.
Suggested essential topics before taking pharmaceutical biotechnology courses can be classified under 16 main topics ( Table 2 ). The topics which were suggested the most were as follows: Biochemistry, Biology, Microbiology, Immunology, Basic Pharmaceutics and Chemistry.
The ultimate objective of all biotechnology research is the development of a commercial product. A variety of basic scientific disciplines contribute to biotechnology to generate different commercial products including drugs [8] , vaccines [9, 10] and diagnostics [11] . This is likely why these suggested topics were found to be essential for pharmaceutical biotechnology. In fact, basic and applied research in pharmaceutical biotechnology work closely together to improve quality ofhealthcare. For example, Problems faced in the production stage can after be solved with the support of the basic research.
The suggested categori-zation of topics for pharmaceutical biotechnology teaching in undergraduate courses of pharmacy education were as follows : Respondents evaluated the suggested 9 main topics either as "very important" or "important". There were very few "less important" evaluations for all of the topics, which is an indication that the proposed topics seem to be regarded as realistic and critical by most respondents. Protein pharmaceuticals are today's most important pharmaceutical biotechnology products and genomics an emerging field, thus explairing the prioritizatin of these two topics. It is important to notice that the topic "Regulatory and Compendia! Aspects" was rated as very important in the responses coming from USA.
Main Topics
Another important result that should be emphasized is the number of replies that came from industry in Europe and America (ten replies in total). This situation could be interpreted as a growing interest and emerging attention of industry to pharmaceutical biotechnology and biopharmaceuticals.
The importance of regulatory processes is related in part to the evaluation of the safety and efficacy of those products as well as the control of appropriate administration for each indication. This is intended to protect the public health and to provide a regulated path for new products to reach the pharmaceutical market. The FDA (Food and Drug Administration) was the first institution assigned to regulating biotechnology products [12] [13] [14] . The EC is proceeding towards a single market and currently approval processes for biotechnology drugs are under consideration [15, 16] . In Japan regulatory requirements are different less stringent [17] . of the production and the control procedures for biotechnology derived products. As a result, several guidelines about the preparation and control of biotechnology-derived drug products have been published in the last ten years.
APPENDIX II SUGGESTED CONTENT FOR UNDER-GRADUATE TEACHING PROGRAM OF
Additional, data was also obtained regarding other topics which were suggested for inclusion in an education program are displayed in Table 3 .
Suggestions coming from academic institutions and industry regarding such additional topics to the proposed program.
Topics suggested in the proposed program to be covered in pharmaceutical biotechnology courses were approved by the respondents of Europe, Asia and America, but further suggestions came from industry in the USA (Table 3) .
Suggestions from industry included "ISO 9000 Standards and More Extensive Regulatory Affairs" topics related to manufacturing of high quality pharmaceutical products.
On the other hand, suggestions related to transgenic animals and biotechnological production of small molecules as antibiotics, vitamins and steroids seem to be very critical.
Some of the recommended topics coming from the respondents such as gene / gene therapy, DNA structures and DNA replication are already present under the suggested content (Appendix II). Recently great interest has been focused on the above mentioned topics [18, 19] .
The final emphasis was on academia and industry perspective to collaborate in a pharmaceutical biotechnology program. From the academia and industry collaboration aspect in pharmaceutical biotechnology the recommendations were centered around; apprenticeship in industry, research training in industry, summer school in industry. 33 of the respondents approved 75:25 (academia/ industry) ratio for this collaboration, 7 of them suggested 50:50 while 3 of them responded as 25:75 and the rest providing no response. In addition to this evaluation, further suggestions came from some of the respondents in 
